Tumor microenvironment (TME) features and serum cytokines in patients with metastatic uveal and cutaneous melanoma treated with tebentafusp

• O. Hamid,
• A. Shoushtari,
• S. Stanhope,
• L. Collins,
• C. Britton-Rivet,
• E. Leach,
• A. Benlahrech,
• K. Ranade,
• J.C. Hassel

Affiliations

O. Hamid

The Angeles Clinic, California, United States of America

A. Shoushtari

Memorial Sloan Kettering Cancer Centre, New York, United States of America

S. Stanhope

Immunocore Ltd, Abingdon, United Kingdom

L. Collins

Immunocore Ltd, Abingdon, United Kingdom

C. Britton-Rivet

Immunocore Ltd, Abingdon, United Kingdom

E. Leach

Immunocore Ltd, Abingdon, United Kingdom

A. Benlahrech

Immunocore Ltd, Abingdon, United Kingdom

K. Ranade

Immunocore Ltd, Abingdon, United Kingdom

J.C. Hassel

University Hospital Heidelberg, Heidelberg, Germany